Financing ·
Adaptive Biotechnologies Corporation announced on June 15, 2026, its intention to offer $250 million in aggregate…
ADPTAdaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation announced on June 15, 2026, its intention to offer $250 million in aggregate principal amount of convertible senior notes due 2031, with a 13-day option for initial purchasers to purchase an additional $37.5 million. The company also announced its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses. Adaptive Biotechnologies is an immunology-focused biotechnology company.